Flanagan SD - Search Results

1

Comparison of furosemide and vinblastine secretion from cell lines overexpressing multidrug resistance protein (P-glycoprotein) and multidrug resistance-associated proteins (MRP1 and MRP2).

Flanagan SD, Cummins CL, Susanto M, Liu X, Takahashi LH, Benet LZ. Flanagan SD, et al. Pharmacology. 2002;64(3):126-34. doi: 10.1159/000056161. Pharmacology. 2002. PMID: 11834888

2

Contributions of saturable active secretion, passive transcellular, and paracellular diffusion to the overall transport of furosemide across adenocarcinoma (Caco-2) cells.

Flanagan SD, Takahashi LH, Liu X, Benet LZ. Flanagan SD, et al. J Pharm Sci. 2002 Apr;91(4):1169-77. doi: 10.1002/jps.10099. J Pharm Sci. 2002. PMID: 11948555

3

Net secretion of furosemide is subject to indomethacin inhibition, as observed in Caco-2 monolayers and excised rat jejunum.

Flanagan SD, Benet LZ. Flanagan SD, et al. Pharm Res. 1999 Feb;16(2):221-24. doi: 10.1023/a:1018868123367. Pharm Res. 1999. PMID: 10100306

4

Pharmacokinetics of Tedizolid in Obese and Nonobese Subjects.

Flanagan S, Minassian SL, Passarell JA, Fiedler-Kelly J, Prokocimer P. Flanagan S, et al. J Clin Pharmacol. 2017 Oct;57(10):1290-1294. doi: 10.1002/jcph.928. Epub 2017 May 16. J Clin Pharmacol. 2017. PMID: 28510339 Clinical Trial. No abstract available.

5

Lack of Effect of Rezafungin on QT/QTc Interval in Healthy Subjects.

Flanagan S, Goodman DB, Jandourek A, O'Reilly T, Sandison T. Flanagan S, et al. Clin Pharmacol Drug Dev. 2020 May;9(4):456-465. doi: 10.1002/cpdd.757. Epub 2019 Dec 2. Clin Pharmacol Drug Dev. 2020. PMID: 31793231 Clinical Trial.

6

Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid.

Flanagan S, Fang E, Muñoz KA, Minassian SL, Prokocimer PG. Flanagan S, et al. Pharmacotherapy. 2014 Sep;34(9):891-900. doi: 10.1002/phar.1458. Epub 2014 Jul 3. Pharmacotherapy. 2014. PMID: 24989138 Free PMC article. Clinical Trial.

7

Reduction in Tedizolid Plasma Exposure among End-Stage Renal Disease Patients Undergoing Dialysis Is Explained by Variations in Ideal Body Weight.

Flanagan S, Prokocimer P. Flanagan S, et al. Antimicrob Agents Chemother. 2016 Apr 22;60(5):3246-7. doi: 10.1128/AAC.03127-15. Print 2016 May. Antimicrob Agents Chemother. 2016. PMID: 26926636 Free PMC article. No abstract available.

8

Pharmacokinetics of Tedizolid and Pseudoephedrine Administered Alone or in Combination in Healthy Volunteers.

Flanagan S, Minassian SL, Prokocimer P. Flanagan S, et al. J Clin Med. 2018 Jun 14;7(6):150. doi: 10.3390/jcm7060150. J Clin Med. 2018. PMID: 29899212 Free PMC article.

9

Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.

Flanagan S, Minassian SL, Morris D, Ponnuraj R, Marbury TC, Alcorn HW, Fang E, Prokocimer P. Flanagan S, et al. Antimicrob Agents Chemother. 2014 Nov;58(11):6471-6. doi: 10.1128/AAC.03431-14. Epub 2014 Aug 18. Antimicrob Agents Chemother. 2014. PMID: 25136024 Free PMC article. Clinical Trial.

10

Tedizolid population pharmacokinetics, exposure response, and target attainment.

Flanagan S, Passarell J, Lu Q, Fiedler-Kelly J, Ludwig E, Prokocimer P. Flanagan S, et al. Antimicrob Agents Chemother. 2014 Nov;58(11):6462-70. doi: 10.1128/AAC.03423-14. Epub 2014 Aug 18. Antimicrob Agents Chemother. 2014. PMID: 25136028 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

146 results

Search Page